muscimol has been researched along with Parkinsonian Disorders in 4 studies
Muscimol: A neurotoxic isoxazole isolated from species of AMANITA. It is obtained by decarboxylation of IBOTENIC ACID. Muscimol is a potent agonist of GABA-A RECEPTORS and is used mainly as an experimental tool in animal and tissue studies.
muscimol : A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Nowak, P | 1 |
| Wang, T | 1 |
| Zhang, L | 1 |
| Zhang, QJ | 1 |
| Wang, Y | 1 |
| Du, CX | 1 |
| Sun, YN | 1 |
| Zhang, J | 1 |
| Lv, SX | 1 |
| Chen, L | 1 |
| Liu, J | 1 |
| Matsumura, M | 1 |
| Kojima, J | 1 |
| Temel, Y | 1 |
| Boothman, LJ | 1 |
| Blokland, A | 1 |
| Magill, PJ | 1 |
| Steinbusch, HW | 1 |
| Visser-Vandewalle, V | 1 |
| Sharp, T | 1 |
4 other studies available for muscimol and Parkinsonian Disorders
| Article | Year |
|---|---|
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Involvement of lateral habenula α1 subunit-containing GABA
Topics: Action Potentials; Animals; Apomorphine; Depression; Dopamine Agonists; GABA Antagonists; GABA-A Rec | 2017 |
The role of the pedunculopontine tegmental nucleus in experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Afferent Pathways; Animals; Basal Ganglia; Brain Stem; | 2001 |
Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus.
Topics: Action Potentials; Animals; Behavior, Animal; Deep Brain Stimulation; Depression; Disease Models, An | 2007 |